Anoro is generally well tolerated1

Please refer to the SmPC for further information on the Anoro Ellipta safety profile prior to prescribing

Support your patients starting on Anoro Ellipta maintenance therapy

References

  1. Anoro Ellipta SmPC

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

© 2021 GSK group of companies or its licensor.
ANORO was developed in collaboration with INNOVIVA.
Trademarks are owned by or licensed to the GSK group of companies.

Innoviva logo

PM-GB-UCV-WCNT-210002 May 2021